PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Journal article

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A Oncology Department, University Hospital Geneva, Geneva, Switzerland.
Banna GL Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

2018-11-06

Published in:

Translational lung cancer research. - 2018

Language

English

Open access status

hybrid

Identifiers

DOI 10.21037/tlcr.2018.07.10
PMID 30393623

Persistent URL

https://sonar.ch/global/documents/232980

Statistics

Document views: 13 File downloads: